Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
KURA Kura Oncology
13.820+0.650+4.94%
Close
01/31 16:00 ET
14.090+0.270+1.95%
Post Mkt Price 01/31 17:50 ET
High
14.330
Open
14.180
Turnover
8.16M
Low
13.550
Pre Close
13.170
Volume
588.99K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Insider Sell: Kura Oncology
05:15 PM EST, 01/31/2023 (MT Newswires) -- Stephen Dale, Chief Medical Officer, on January 27, 2023, sold 9,225 shares in Kura Oncology (KURA) for $128,033. Following the Form 4 filing with the SEC, D
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
UpgradesFor Silvercorp Metals Inc (AMEX:SVM), Raymond James upgraded the previous rating of Market Perform to Outperform. Silvercorp Metals earned $0.04 in the second quarter, compared to $0.08 in the
Kura Oncology Started at Buy With $25 Stock Price Target at Stifel Nicolaus
Kura Oncology Started at Buy With $25 Stock Price Target at Stifel Nicolaus
Kura Oncology Initiated at Buy by Stifel
Kura Oncology Price Target Announced at $25.00/Share by Stifel
Kura Oncology Price Target Announced at $25.00/Share by Stifel
Kura Oncology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/31/2023 89.83% Stifel → $25 Initiates Coverage On → Buy 07/13/2022 120.2% Credit Suisse $27 → $29 Maint
Stifel Initiates Coverage On Kura Oncology With Buy Rating, Announces Price Target of $25
Stifel analyst Bradley Canino initiates coverage on Kura Oncology (NASDAQ:KURA) with a Buy rating and announces Price Target of $25.
Kura Oncology (NASDAQ:KURA) Earns Buy Rating From Analysts at Stifel Nicolaus
Analysts at Stifel Nicolaus initiated coverage on shares of Kura Oncology (NASDAQ:KURA – Get Rating) in a research report issued to clients and investors on Monday, The Fly reports. The firm set a "b
Kura Oncology Initiated With a Buy at Stifel
Victory Capital Management Inc. Raises Stake in Kura Oncology, Inc. (NASDAQ:KURA)
Victory Capital Management Inc. boosted its position in Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) by 77.2% during the third quarter, Holdings Channel.com reports. The institutional investor ow
Company Overview
More
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
CEO： Dr. Troy E. Wilson, PhD, J.D.
Market： NASDAQ
Listing Date： 11/05/2015
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet